| First Author | Nonogaki K | Year | 2017 |
| Journal | Neurosci Lett | Volume | 638 |
| Pages | 35-38 | PubMed ID | 27939978 |
| Mgi Jnum | J:241444 | Mgi Id | MGI:5902648 |
| Doi | 10.1016/j.neulet.2016.12.008 | Citation | Nonogaki K, et al. (2017) alpha1-Adrenergic receptor downregulates hepatic FGF21 production and circulating FGF21 levels in mice. Neurosci Lett 638:35-38 |
| abstractText | Fibroblast growth factor 21 (FGF21) is primarily secreted by the liver as an endocrine hormone and is suggested as a promising target for the treatment of metabolic diseases. FGF21 acts centrally to exert its effects on energy expenditure and body weight via the sympathetic nervous system in mice. Here we show that intraperitoneal injection of phentolamine (an alpha-adrenergic receptor antagonist, 5mg/kg) significantly increased plasma FGF21 levels compared with the saline controls in C57BL6J mice, whereas alprenolol (a beta-adrenergic receptor antagonist, 6mg/kg) had no effect. In addition, intraperitoneal injection of prazosin (an alpha1-adrenergic receptor antagonist, 5mg/kg) significantly increased plasma FGF21 levels compared with the controls, whereas yohimbine (an alpha2-adrenergic receptor antagonist, 5mg/kg) had no effect. Moreover, the treatment with prazosin significantly increased the expression of hepatic FGF21, while having no effect on the expression of hepatic PPARalpha and PPARgamma. After a 5-h fast, intraperitoneal injection of prazosin significantly increased plasma FGF21 levels and impaired glucose tolerance compared with controls. These findings suggest that alpha1-adrenergic receptor downregulates the expression of hepatic FGF21 and plasma FGF21 levels independently of feeding and hepatic PPARalpha and PPARgamma expression in mice, and that the increases in circulating FGF21 levels might be related to impaired glucose tolerance. |
